MedTrace Logo

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

NCT01639911 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-07-22

No results posted yet for this study

Summary

This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously treated non-hematologic solid tumors.

Conditions

  • Malignant Neoplasm of Breast
  • CNS Malignancy
  • Malignant Neoplasm of Gastrointestinal Tract
  • Genitourinary Neoplasms Malignancy and Gender Unspecified
  • Head and Neck Neoplasms
  • Melanoma
  • Malignant Neoplasm of Thorax

Interventions

DRUG

Alisertib

Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.

DRUG

Pazopanib

Pazopanib at the assigned dose once a day continuously for the duration of treatment.

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Arkadiusz Z. Dudek, M.D. · University of Illinois at Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-14
Primary Completion
2016-07-28
Completion
2016-07-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01639911 on ClinicalTrials.gov